Pub Date : 2016-12-12DOI: 10.4172/2329-6917.1000E119
Ling Zhang
Bone marrow failure syndromes (BMFS) are a cluster of inherited or acquired disorders characterized by peripheral cytopenia due to a decrease in hematopoietic progenitors or dysregulated hematopoiesis. Inherited bone marrow failure syndromes are mainly found in pediatric group, encompassing Diamond Blackfan anemia (DBA), Fanconi anemia (FA), congenital sideroblastic anemia (CSA), congenital neutropenia (CN), congenital dyserythropoiestic anemia (CDA), Shwachman Diamond syndrome (SDS), and dyskeratosis congenita (DC) [1], In contrast, acquired bone marrow syndromes are more commonly seen in adults and mainly include acquired aplastic anemia (AA), acquired megakaryocytic thrombocytopenia (AMT), paroxysmal nocturnal hemoglobinuria (PNH), and myelodysplastic syndromes (MDS).
{"title":"Inherited and Acquired Bone Marrow Failure Syndromes: In the Era of DeepGene Sequencing","authors":"Ling Zhang","doi":"10.4172/2329-6917.1000E119","DOIUrl":"https://doi.org/10.4172/2329-6917.1000E119","url":null,"abstract":"Bone marrow failure syndromes (BMFS) are a cluster of inherited or acquired disorders characterized by peripheral cytopenia due to a decrease in hematopoietic progenitors or dysregulated hematopoiesis. Inherited bone marrow failure syndromes are mainly found in pediatric group, encompassing Diamond Blackfan anemia (DBA), Fanconi anemia (FA), congenital sideroblastic anemia (CSA), congenital neutropenia (CN), congenital dyserythropoiestic anemia (CDA), Shwachman Diamond syndrome (SDS), and dyskeratosis congenita (DC) [1], In contrast, acquired bone marrow syndromes are more commonly seen in adults and mainly include acquired aplastic anemia (AA), acquired megakaryocytic thrombocytopenia (AMT), paroxysmal nocturnal hemoglobinuria (PNH), and myelodysplastic syndromes (MDS).","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"3 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2016-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2329-6917.1000E119","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70270302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-26DOI: 10.4172/2329-6917.1000222
Lynh Nguyen, J. Bowers, Dahui Qin, Ling Zhang
A secondary myeloid or lymphoid neoplasm is not infrequently associated with a primary tumor, solid or hematopoietic, post cytotoxic treatment or radiation. Concurrent secondary neoplasms derived from distinct myeloid and lymphoid cell origins are rare. It is not only a diagnostic challenge, but makes for difficult treatment management. We report a very rare occurrence in 63-year-old male with a history of high-grade follicular lymphoma who was treated with multiple courses of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) and then developed a concurrent secondary peripheral T-cell lymphoma, not otherwise specified (sPTCL, NOS) and therapy-related myeloid neoplasm (tMN), under an umbrella of myelodysplastic/myeloproliferative neoplasm, namely chronic myelomonocytic leukemia (CMML). Despite aggressive therapeutic management, the patient passed away secondary to disease progression, complications of infection, and multi-organ failure. An appropriate diagnostic approach for complicated cases as described aided in providing the correct diagnosis.
{"title":"Concomitant Secondary Peripheral T-cell Lymphoma with Therapy-related Chronic Myelomonocytic Leukemia in a Patient with History of High-grade Follicular Lymphoma","authors":"Lynh Nguyen, J. Bowers, Dahui Qin, Ling Zhang","doi":"10.4172/2329-6917.1000222","DOIUrl":"https://doi.org/10.4172/2329-6917.1000222","url":null,"abstract":"A secondary myeloid or lymphoid neoplasm is not infrequently associated with a primary tumor, solid or \u0000 hematopoietic, post cytotoxic treatment or radiation. Concurrent secondary neoplasms derived from distinct myeloid \u0000 and lymphoid cell origins are rare. It is not only a diagnostic challenge, but makes for difficult treatment \u0000 management. We report a very rare occurrence in 63-year-old male with a history of high-grade follicular lymphoma who was treated with multiple courses of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) \u0000 and then developed a concurrent secondary peripheral T-cell lymphoma, not otherwise specified (sPTCL, \u0000 NOS) and therapy-related myeloid neoplasm (tMN), under an umbrella of myelodysplastic/myeloproliferative \u0000 neoplasm, namely chronic myelomonocytic leukemia (CMML). Despite aggressive therapeutic management, the \u0000 patient passed away secondary to disease progression, complications of infection, and multi-organ failure. An \u0000 appropriate diagnostic approach for complicated cases as described aided in providing the correct diagnosis.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"4 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2016-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-25DOI: 10.4172/2329-6917.1000221
G. Salih
Introduction: In order to detect the mutation variants of BCR-ABL fusion genes that lead to leukemia in human, 30 blood samples from chronic myeloid leukemia patients and 10 blood samples from apparently healthy people (as control) were collected and tested hematologically, morphologically and by amplification of the fusion mRNA by RT-PCR. The e1a3 variant was detected by amplification of 309 bp from the fusion of exons 1 of bcr and exon 3 of abl gene. Materials and method: Application of RT-PCR assay to detect the prevalence and frequency of ela3 and ela2 variants in CML patients and in routine diagnosis of the most common leukemia translocations. Results: The RT-PCR showed that out of 30 patients, 23 (76.6%) were with e1a3 mutation variant and 7 (23.3%) were negative for e1a2 and e1a3 variants. All the 10 control samples showed no mutations related to these variants. Conclusion: The e1a3 variant was detected by amplification of 309 bp from the fusion of exons 1 of bcr and exon 3 of abl gene and the RT-PCR showed that out of 30 patients, 23 (76.6%) were with e1a3 mutation variant and 7 (23.3%) were negative for e1a2 and e1a3 variants, while the 10 control samples showed no mutations related to these variants.
{"title":"Detection of a High Frequency of e1a3/BCR-ABL in Chronic Myeloid Leukemia Patients of Sulaimania Province by RT-PCR","authors":"G. Salih","doi":"10.4172/2329-6917.1000221","DOIUrl":"https://doi.org/10.4172/2329-6917.1000221","url":null,"abstract":"Introduction: In order to detect the mutation variants of BCR-ABL fusion genes that lead to leukemia in human, \u0000 30 blood samples from chronic myeloid leukemia patients and 10 blood samples from apparently healthy people \u0000 (as control) were collected and tested hematologically, morphologically and by amplification of the fusion mRNA by \u0000 RT-PCR. The e1a3 variant was detected by amplification of 309 bp from the fusion of exons 1 of bcr and exon 3 of \u0000 abl gene. \u0000 Materials and method: Application of RT-PCR assay to detect the prevalence and frequency of ela3 and ela2 \u0000 variants in CML patients and in routine diagnosis of the most common leukemia translocations. \u0000 Results: The RT-PCR showed that out of 30 patients, 23 (76.6%) were with e1a3 mutation variant and 7 (23.3%) \u0000 were negative for e1a2 and e1a3 variants. All the 10 control samples showed no mutations related to these variants. \u0000 Conclusion: The e1a3 variant was detected by amplification of 309 bp from the fusion of exons 1 of bcr and \u0000 exon 3 of abl gene and the RT-PCR showed that out of 30 patients, 23 (76.6%) were with e1a3 mutation variant and \u0000 7 (23.3%) were negative for e1a2 and e1a3 variants, while the 10 control samples showed no mutations related to \u0000 these variants.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"4 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2016-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-10-31DOI: 10.4172/2329-6917.1000220
K. Inokuchi, Muneo Okamoto, K. Nakayama, H. Tamai, H. Yamaguchi
A 21-year-old man who was diagnosed with chronic-phase CML and treated with imatinib (400 mg/day) during September 2004 achieved a complete molecular response within 14 months. His liver function remained normal during this period. The results of liver function tests after four years of treatment showed AST, 547 IU/L; ALT, 1124 IU/L, and viral hepatitis and autoimmune hepatitis were undetectable. Drug toxicity was suspected and imatinib was immediately discontinued. A liver biopsy showed hemorrhagic necrosis and hemosiderin deposition around the central vein indicating a diagnosis of imatinib-induced liver failure. Aminotransferases normalized within three months after imatinib withdrawal. Seven months after imatinib discontinuation, bcr-abl transcripts were detected twice during the next four months. Thus, dasatinib (100 mg) was administered, which resulted in an undetectable molecular response within two months. The patient decided to stop taking dasatinib two years after achieving the undetectable molecular response and he has remained in this condition for four years since. Patients with liver damage require follow-up. To confirm the benefit of changing medication from imatinib or other drugs to dasatinib will require more information from accumulated cases.
{"title":"Late-onset Imatinib-induced Liver Failure Treated with Dasatinib for Two Years Resulted in Long-term Undetectable Response","authors":"K. Inokuchi, Muneo Okamoto, K. Nakayama, H. Tamai, H. Yamaguchi","doi":"10.4172/2329-6917.1000220","DOIUrl":"https://doi.org/10.4172/2329-6917.1000220","url":null,"abstract":"A 21-year-old man who was diagnosed with chronic-phase CML and treated with imatinib (400 mg/day) during September 2004 achieved a complete molecular response within 14 months. His liver function remained normal during this period. The results of liver function tests after four years of treatment showed AST, 547 IU/L; ALT, 1124 IU/L, and viral hepatitis and autoimmune hepatitis were undetectable. Drug toxicity was suspected and imatinib was immediately discontinued. A liver biopsy showed hemorrhagic necrosis and hemosiderin deposition around the central vein indicating a diagnosis of imatinib-induced liver failure. Aminotransferases normalized within three months after imatinib withdrawal. Seven months after imatinib discontinuation, bcr-abl transcripts were detected twice during the next four months. Thus, dasatinib (100 mg) was administered, which resulted in an undetectable molecular response within two months. The patient decided to stop taking dasatinib two years after achieving the undetectable molecular response and he has remained in this condition for four years since. Patients with liver damage require follow-up. To confirm the benefit of changing medication from imatinib or other drugs to dasatinib will require more information from accumulated cases.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"4 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2016-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-10-30DOI: 10.4172/2329-6917.1000219
M. Elrahman, D. Nigm, Azza A Abo Elfadle
Objectives: Recently, hyperactivation of the Wnt signaling pathway has been implicated in leukomogenesis, so we studied the epigenetic dysfunction of SFRP1,2 and expression of interleukin2 receptor α chain (IL2Rα, also known as CD25) and its prognostic impact in acute myeloblastic leukemia (AML). Methods: We studied the methylation profile of SFRP1,2 in AML cells by methylation-specific polymerase chain reaction (MSP) and the hyper expression of IL2Rα (CD25) by flowcytometry. Results: We analyzed the methylation profile of SFRP1,2 in 40 de novo AML patients. The percentage of hypermethylation in the patient samples were 37.5% for SFRP1, 12.5% for SFRP2. CD25 was positive in 12(30%) of 40 patients AML. We found that in patients whom 60 years and younger with intermediate risk cytogenetics in de novo AML, hypermethylation of SFRP1 and CD25 were accompanied with relapse (P=0.024). Conclusion: Our data indicates that in a subgroup of AML patients, hypermethylation of SFRP1 and high expression of CD25 predict relapse
{"title":"Methylated SFRP1,2 and CD25 Expression in Acute Myeloid Leukemia Play an Important Role in the Pathogenesis of the Disease and in Turn in its Treatment","authors":"M. Elrahman, D. Nigm, Azza A Abo Elfadle","doi":"10.4172/2329-6917.1000219","DOIUrl":"https://doi.org/10.4172/2329-6917.1000219","url":null,"abstract":"Objectives: Recently, hyperactivation of the Wnt signaling pathway has been implicated in leukomogenesis, so we studied the epigenetic dysfunction of SFRP1,2 and expression of interleukin2 receptor α chain (IL2Rα, also known as CD25) and its prognostic impact in acute myeloblastic leukemia (AML). Methods: We studied the methylation profile of SFRP1,2 in AML cells by methylation-specific polymerase chain reaction (MSP) and the hyper expression of IL2Rα (CD25) by flowcytometry. Results: We analyzed the methylation profile of SFRP1,2 in 40 de novo AML patients. The percentage of hypermethylation in the patient samples were 37.5% for SFRP1, 12.5% for SFRP2. CD25 was positive in 12(30%) of 40 patients AML. We found that in patients whom 60 years and younger with intermediate risk cytogenetics in de novo AML, hypermethylation of SFRP1 and CD25 were accompanied with relapse (P=0.024). Conclusion: Our data indicates that in a subgroup of AML patients, hypermethylation of SFRP1 and high expression of CD25 predict relapse","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"4 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2016-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-10-15DOI: 10.4172/2329-6917.1000218
Piro Eugenio, L. Luciano, Kropp Mariagrazia, Molica Stefano
Bacillus cereus is an aerobic Gram-positive spore forming rod that is ubiquitous in the environment. A case of severe infection due to Bacillus cereus isolated on the tip of central venous catheter (CVC) of a patient with acute lymphoblastic leukemia (ALL) is reported here. We point out the role played by a rapid diagnosis of Bacillus cereus sepsis and early therapeutic intervention in the control of this life-threatening infection
{"title":"Bacillus cereus Catheter-Related Infection in Acute Lymphoblastic Leukemia(ALL) Patient: A Case Report and Review of Literature","authors":"Piro Eugenio, L. Luciano, Kropp Mariagrazia, Molica Stefano","doi":"10.4172/2329-6917.1000218","DOIUrl":"https://doi.org/10.4172/2329-6917.1000218","url":null,"abstract":"Bacillus cereus is an aerobic Gram-positive spore forming rod that is ubiquitous in the environment. A case of severe infection due to Bacillus cereus isolated on the tip of central venous catheter (CVC) of a patient with acute lymphoblastic leukemia (ALL) is reported here. We point out the role played by a rapid diagnosis of Bacillus cereus sepsis and early therapeutic intervention in the control of this life-threatening infection","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"4 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2016-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-09-15DOI: 10.4172/2329-6917.1000217
Sabrina Fischer, N. Echeverría, J. Cristina, P. Moreno
Human endogenous retrovirus (HERVs) integrated in the human genome millions of years ago and became a stable part of the inherited genetic material. Most of these HERVs are dysfunctional due to numerous mutations and thus making it impossible to generate a full, infectious retrovirus particle from a single genetic locus. However, many HERVs are still exceptionally well preserved and maintain Open Reading Frames encoding functional viral proteins. The permanence of HERV´s genes along evolution suggests that these elements have proven beneficial to human survival. In this regard, the expression of certain HERV proteins is implicated in important physiological functions, such as placental development. Nevertheless, reactivation of HERVs has frequently been observed in a variety of human tumors suggesting their potential to contribute to malignant progression. Considering the role of HERVs in the carcinogenesis process, the purpose of this mini review is to deepen into HERVs expression and its possible implication in hemato-oncologic disease development.
{"title":"Human Endogenous Retrovirus: Their Relationship with Hematological Diseases","authors":"Sabrina Fischer, N. Echeverría, J. Cristina, P. Moreno","doi":"10.4172/2329-6917.1000217","DOIUrl":"https://doi.org/10.4172/2329-6917.1000217","url":null,"abstract":"Human endogenous retrovirus (HERVs) integrated in the human genome millions of years ago and became a stable part of the inherited genetic material. Most of these HERVs are dysfunctional due to numerous mutations and thus making it impossible to generate a full, infectious retrovirus particle from a single genetic locus. However, many HERVs are still exceptionally well preserved and maintain Open Reading Frames encoding functional viral proteins. The permanence of HERV´s genes along evolution suggests that these elements have proven beneficial to human survival. In this regard, the expression of certain HERV proteins is implicated in important physiological functions, such as placental development. Nevertheless, reactivation of HERVs has frequently been observed in a variety of human tumors suggesting their potential to contribute to malignant progression. Considering the role of HERVs in the carcinogenesis process, the purpose of this mini review is to deepen into HERVs expression and its possible implication in hemato-oncologic disease development.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"4 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2016-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2329-6917.1000217","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-09-07DOI: 10.4172/2329-6917.1000215
S. Zareifar, N. Shakibazad, Gholamreza Fathpour, Mehrpour Moradi, Fazl Saleh
Acute lymphoblastic leukemia (ALL) has several clinical manifestations on the base of bone marrow infiltration and the extent of extra medullary involvement. Anterior chest wall bulging as an initial presentation is rare. The aim of this case report study is to present a 3.5 year-old-boy presented with anterior chest wall bulging without history of trauma since 1 month ago. Tc99m-MDP bone scan showed multifocal active bony pathology in sternum, lower thoracic and all lumbar vertebra and right sacral ala. Bone marrow aspiration and biopsy was in favor of acute precursor lymphoblastic leukemia, B cell type. Therefore, acute lymphoblastic leukemia has different initial presentation and anterior chest wall bulging can be a rare initial sign of acute lymphoblastic leukemia in children.
{"title":"Anterior Chest Wall Bulging: A Rare Initial Manifestation of Acute Lymphoblastic Leukemia in a Child","authors":"S. Zareifar, N. Shakibazad, Gholamreza Fathpour, Mehrpour Moradi, Fazl Saleh","doi":"10.4172/2329-6917.1000215","DOIUrl":"https://doi.org/10.4172/2329-6917.1000215","url":null,"abstract":"Acute lymphoblastic leukemia (ALL) has several clinical manifestations on the base of bone marrow infiltration and the extent of extra medullary involvement. Anterior chest wall bulging as an initial presentation is rare. The aim of this case report study is to present a 3.5 year-old-boy presented with anterior chest wall bulging without history of trauma since 1 month ago. Tc99m-MDP bone scan showed multifocal active bony pathology in sternum, lower thoracic and all lumbar vertebra and right sacral ala. Bone marrow aspiration and biopsy was in favor of acute precursor lymphoblastic leukemia, B cell type. Therefore, acute lymphoblastic leukemia has different initial presentation and anterior chest wall bulging can be a rare initial sign of acute lymphoblastic leukemia in children.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"4 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2016-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2329-6917.1000215","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-09-07DOI: 10.4172/2329-6917.1000213
S. Zareifar, B. Kazemi, Arzanian Mt, M. ehpour
Background: Efforts were made in order to identify the etiologic factors in pediatric cancers. Several studies have suggested a probable etiologic association between lymphoma and Epstein-Barr virus (EBV); therefore, the aim of this study was to investigate the association of EBV in childhood lymphoma. Materials and method: Paraffin block of 63 pediatric patients with lymphoma was studied for detection of EBV latent membrane protein 1 (LMP-1). The clinical data regarding age, sex, type of lymphoma and histology, stage of the disease of the patients treated in a retrospective consecutive manner for 5 years were used. Results: Sixty-three eligible patients including 41 (65%) patients with non-Hodgkin lymphoma (NHL) and 22 (34.9%) of Hodgkin lymphoma (HL) were assessed. The male to female ratio was 3.84/1. Regarding the gender, the overall difference between NHL and HL was statistically significant. With respect to age, the difference between HL and NHL was not significant. EBV LMP1 gene transcripts were found in 65.8% of children with NHL and 59% of children with HL. Regarding the type of lymphoma, LMP1 positivity was not statistically significant (P=0.087). Conclusion: EBV infection may be a factor involved in the high incidence of pediatric lymphoma; our study suggests a positive influence of EBV infection in pediatric lymphomas.
{"title":"Detection of EpsteinâÂÂBarr virus in Pediatric Lymphoma: A Single Center Study","authors":"S. Zareifar, B. Kazemi, Arzanian Mt, M. ehpour","doi":"10.4172/2329-6917.1000213","DOIUrl":"https://doi.org/10.4172/2329-6917.1000213","url":null,"abstract":"Background: Efforts were made in order to identify the etiologic factors in pediatric cancers. Several studies have suggested a probable etiologic association between lymphoma and Epstein-Barr virus (EBV); therefore, the aim of this study was to investigate the association of EBV in childhood lymphoma. \u0000Materials and method: Paraffin block of 63 pediatric patients with lymphoma was studied for detection of EBV latent membrane protein 1 (LMP-1). The clinical data regarding age, sex, type of lymphoma and histology, stage of the disease of the patients treated in a retrospective consecutive manner for 5 years were used. \u0000Results: Sixty-three eligible patients including 41 (65%) patients with non-Hodgkin lymphoma (NHL) and 22 (34.9%) of Hodgkin lymphoma (HL) were assessed. The male to female ratio was 3.84/1. Regarding the gender, the overall difference between NHL and HL was statistically significant. With respect to age, the difference between HL and NHL was not significant. EBV LMP1 gene transcripts were found in 65.8% of children with NHL and 59% of children with HL. Regarding the type of lymphoma, LMP1 positivity was not statistically significant (P=0.087). \u0000Conclusion: EBV infection may be a factor involved in the high incidence of pediatric lymphoma; our study suggests a positive influence of EBV infection in pediatric lymphomas.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"4 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2016-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2329-6917.1000213","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-09-07DOI: 10.4172/2329-6917.1000216
D. Benharroch
An association between measles virus (MV) proteins and RNA and classical Hodgkin lymphoma (cHL) was first demonstrated by immunohistochemistry, RT-PCR and in situ hybridization, in 2004 [1]. We used several commercial and experimental anti-MV antibodies. Total RNA was extracted from all available snap-frozen tissue and from a few FFPE tissues out of a random cohort of 154 cHL untreated patients. Of the 154 biopsies, 82 (54%) were positive for at least two MV antigens. By Southern blot, 4 of 15 hemagglutinin (HA) MVRNAs, as well as 2 of 16 nucleoprotein (NP) MV-RNAs were positive. In situ hybridization showed that 2 of 7 HA and 8 of 21 NP-MV-RNAs were positive [1].
{"title":"Letter to the Editor: Classical Hodgkin Lymphoma and the Measles Virus","authors":"D. Benharroch","doi":"10.4172/2329-6917.1000216","DOIUrl":"https://doi.org/10.4172/2329-6917.1000216","url":null,"abstract":"An association between measles virus (MV) proteins and RNA and classical Hodgkin lymphoma (cHL) was first demonstrated by immunohistochemistry, RT-PCR and in situ hybridization, in 2004 [1]. We used several commercial and experimental anti-MV antibodies. Total RNA was extracted from all available snap-frozen tissue and from a few FFPE tissues out of a random cohort of 154 cHL untreated patients. Of the 154 biopsies, 82 (54%) were positive for at least two MV antigens. By Southern blot, 4 of 15 hemagglutinin (HA) MVRNAs, as well as 2 of 16 nucleoprotein (NP) MV-RNAs were positive. In situ hybridization showed that 2 of 7 HA and 8 of 21 NP-MV-RNAs were positive [1].","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"4 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2016-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：